Fundraising FoxOUP (Osage University Partners) — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in
Co-investorsNextech InvestTorrey Pines Investment
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesHarpoon VenturesLongeVC+7 more
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.
HealthtechMedical DevicesLexington, US
Carl Vause(Executive Officer, Director)inMira Sahney(Executive Officer, Director)inDavid Myung(Director)
BoardMichael Hawkins(Director)Wende Hutton(Director)inWilliam Harrington(Director)in
Co-investorsCanaan PartnersTreo Ventures, LlcJohnson & Johnson Innovation – JJDCOsage University Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.